85 related articles for article (PubMed ID: 12115105)
41. Anti-HIV agents. Saquinavir with fosamprenavir.
TreatmentUpdate; 2004; 16(3):9. PubMed ID: 17219609
[No Abstract] [Full Text] [Related]
42. Bioactive substances of garlic and their role in dietoprophylaxis and dietotherapy.
Swiderski F; Dabrowska M; Rusaczonek A; Waszkiewicz-Robak B
Rocz Panstw Zakl Hig; 2007; 58(1):41-6. PubMed ID: 17711089
[TBL] [Abstract][Full Text] [Related]
43. Effect of quercetin on the plasma and intracellular concentrations of saquinavir in healthy adults.
DiCenzo R; Frerichs V; Larppanichpoonphol P; Predko L; Chen A; Reichman R; Morris M
Pharmacotherapy; 2006 Sep; 26(9):1255-61. PubMed ID: 16945047
[TBL] [Abstract][Full Text] [Related]
44. [Biologically active substances in garlic (Allium sativum L.) and their application in nutrition for humans].
Ryzhenkov VE; Makarov VG
Vopr Pitan; 2003; 72(4):42-6. PubMed ID: 12968304
[TBL] [Abstract][Full Text] [Related]
45. The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells.
McLean K; VanDeVen NA; Sorenson DR; Daudi S; Liu JR
Gynecol Oncol; 2009 Mar; 112(3):623-30. PubMed ID: 19147209
[TBL] [Abstract][Full Text] [Related]
46. Amplification of vacuole-targeting fungicidal activity of antibacterial antibiotic polymyxin B by allicin, an allyl sulfur compound from garlic.
Ogita A; Nagao Y; Fujita K; Tanaka T
J Antibiot (Tokyo); 2007 Aug; 60(8):511-8. PubMed ID: 17827662
[TBL] [Abstract][Full Text] [Related]
47. Enhancement of the fungicidal activity of amphotericin B by allicin, an allyl-sulfur compound from garlic, against the yeast Saccharomyces cerevisiae as a model system.
Ogita A; Fujita K; Taniguchi M; Tanaka T
Planta Med; 2006 Oct; 72(13):1247-50. PubMed ID: 16902870
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
49. Structure, dynamics and solvation of HIV-1 protease/saquinavir complex in aqueous solution and their contributions to drug resistance: molecular dynamic simulations.
Wittayanarakul K; Aruksakunwong O; Sompornpisut P; Sanghiran-Lee V; Parasuk V; Pinitglang S; Hannongbua S
J Chem Inf Model; 2005; 45(2):300-8. PubMed ID: 15807491
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A
Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
[TBL] [Abstract][Full Text] [Related]
51. Development and validation of a reversed-phase liquid chromatographic method with fluorescence detection for the study of Saquinavir pharmacokinetics in rat plasma.
Pathak SM; Kumar AR; Subramanian G; Udupa N
Anal Chim Acta; 2007 Jul; 594(2):248-56. PubMed ID: 17586122
[TBL] [Abstract][Full Text] [Related]
52. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.
Chappuy H; Tréluyer JM; Rey E; Dimet J; Fouché M; Firtion G; Pons G; Mandelbrot L
Am J Obstet Gynecol; 2004 Aug; 191(2):558-62. PubMed ID: 15343237
[TBL] [Abstract][Full Text] [Related]
53. Saquinavir, the pioneer antiretroviral protease inhibitor.
la Porte CJ
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1313-22. PubMed ID: 19737048
[TBL] [Abstract][Full Text] [Related]
54. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.
Pajonk F; Himmelsbach J; Riess K; Sommer A; McBride WH
Cancer Res; 2002 Sep; 62(18):5230-5. PubMed ID: 12234989
[TBL] [Abstract][Full Text] [Related]
55. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
[TBL] [Abstract][Full Text] [Related]
56. Drug interactions. Coming soon--a new formulation of saquinavir (Invirase).
TreatmentUpdate; 2006; 18(3):9. PubMed ID: 17209243
[No Abstract] [Full Text] [Related]
57. Synthesis of allicin and purification by solid-phase extraction.
Cruz-Villalon G
Anal Biochem; 2001 Mar; 290(2):376-8. PubMed ID: 11237342
[No Abstract] [Full Text] [Related]
58. Antibacterial activity of garlic and onions: a historical perspective.
Farbman KS; Barnett ED; Bolduc GR; Klein JO
Pediatr Infect Dis J; 1993 Jul; 12(7):613-4. PubMed ID: 8346006
[No Abstract] [Full Text] [Related]
59. Garlic: the key to sophisticated lowering of hepatocellular lipid.
Gebhardt R
Nutrition; 1997 Apr; 13(4):379-80. PubMed ID: 9178295
[No Abstract] [Full Text] [Related]
60. Effect of ketoconazole on plasma concentrations of saquinavir.
Collazos J; Martinez E; Mayo J; Blanco MS
J Antimicrob Chemother; 2000 Jul; 46(1):151-2. PubMed ID: 10882711
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
